|
1
|
Mittal S and El-Serag HB: Epidemiology of
hepatocellular carcinoma: Consider the population. J Clin
Gastroenterol. 47:(Suppl). S2–S6. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Roxburgh P and Evans TR: Systemic therapy
of hepatocellular carcinoma: Are we making progress? Adv Ther.
25:1089–1104. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
de Lope CR, Tremosini S, Forner A, Reig M
and Bruix J: Management of HCC. J Hepatol. 56:(Suppl 1). S75–S87.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bruix J and Sherman M: Practice Guidelines
Committee, American Association for the Study of Liver Diseases:
Management of hepatocellular carcinoma. Hepatology. 42:1208–1236.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mann CD, Neal CP, Garcea G, Manson MM,
Dennison AR and Berry DP: Prognostic molecular markers in
hepatocellular carcinoma: A systematic review. Eur J Cancer.
43:979–992. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Poon RT: Prevention of recurrence after
resection of hepatocellular carcinoma: A daunting challenge.
Hepatology. 54:757–759. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chignard N, Shang S, Wang H, Marrero J,
Bréchot C, Hanash S and Beretta L: Cleavage of endoplasmic
reticulum proteins in hepatocellular carcinoma: Detection of
generated fragments in patient sera. Gastroenterology.
130:2010–2022. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Corona G, De Lorenzo E, Elia C, Simula MP,
Avellini C, Baccarani U, Lupo F, Tiribelli C, Colombatti A and
Toffoli G: Differential proteomic analysis of hepatocellular
carcinoma. Int J Oncol. 36:93–99. 2010.PubMed/NCBI
|
|
9
|
Huang X, Zeng Y, Xing X, Zeng J, Gao Y,
Cai Z, Xu B, Liu X, Huang A and Liu J: Quantitative proteomics
analysis of early recurrence/metastasis of huge hepatocellular
carcinoma following radical resection. Proteome Sci. 12:222014.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Teramoto R, Minagawa H, Honda M, Miyazaki
K, Tabuse Y, Kamijo K, Ueda T and Kaneko S: Protein expression
profile characteristic to hepatocellular carcinoma revealed by
2D-DIGE with supervised learning. Biochim Biophys Acta.
1784:764–772. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yokoo H, Kondo T, Okano T, Nakanishi K,
Sakamoto M, Kosuge T, Todo S and Hirohashi S: Protein expression
associated with early intrahepatic recurrence of hepatocellular
carcinoma after curative surgery. Cancer Sci. 98:665–673. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gustafsson OJ, Arentz G and Hoffmann P:
Proteomic developments in the analysis of formalin-fixed tissue.
Biochim Biophys Acta. 1854:559–580. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Edge SB and Compton CC: The American Joint
Committee on Cancer: The 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bradford MM: A rapid and sensitive method
for the quantitation of microgram quantities of protein utilizing
the principle of protein-dye binding. Anal Biochem. 72:248–254.
1976. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zybailov B, Coleman MK, Florens L and
Washburn MP: Correlation of relative abundance ratios derived from
peptide ion chromatograms and spectrum counting for quantitative
proteomic analysis using stable isotope labeling. Anal Chem.
77:6218–6224. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Old WM, Meyer-Arendt K, Aveline-Wolf L,
Pierce KG, Mendoza A, Sevinsky JR, Resing KA and Ahn NG: Comparison
of label-free methods for quantifying human proteins by shotgun
proteomics. Mol Cell Proteomics. 4:1487–1502. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
da W Huang, Sherman BT, Stephens R,
Baseler MW, Lane HC and Lempicki RA: DAVID gene ID conversion tool.
Bioinformation. 2:428–430. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Paulsson K and Wang P: Chaperones and
folding of MHC class I molecules in the endoplasmic reticulum.
Biochim Biophys Acta. 1641:1–12. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Turano C, Gaucci E, Grillo C and
Chichiarelli S: ERp57/GRP58: A protein with multiple functions.
Cell Mol Biol Lett. 16:539–563. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Celli CM and Jaiswal AK: Role of GRP58 in
mitomycin C-induced DNA cross-linking. Cancer Res. 63:6016–6025.
2003.PubMed/NCBI
|
|
22
|
Chay D, Cho H, Lim BJ, Kang ES, Oh YJ,
Choi SM, Kim BW, Kim YT and Kim JH: ER-60 (PDIA3) is highly
expressed in a newly established serous ovarian cancer cell line,
YDOV-139. Int J Oncol. 37:399–412. 2010.PubMed/NCBI
|
|
23
|
Liao CJ, Wu TI, Huang YH, Chang TC, Wang
CS, Tsai MM, Lai CH, Liang Y, Jung SM and Lin KH: Glucose-regulated
protein 58 modulates cell invasiveness and serves as a prognostic
marker for cervical cancer. Cancer Sci. 102:2255–2263. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chung H, Cho H, Perry C, Song J, Ylaya K,
Lee H and Kim JH: Downregulation of ERp57 expression is associated
with poor prognosis in early-stage cervical cancer. Biomarkers.
18:573–579. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Leys CM, Nomura S, LaFleur BJ, Ferrone S,
Kaminishi M, Montgomery E and Goldenring JR: Expression and
prognostic significance of prothymosin-alpha and ERp57 in human
gastric cancer. Surgery. 141:41–50. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Corazzari M, Lovat PE, Armstrong JL, Fimia
GM, Hill DS, Birch-Machin M, Redfern CP and Piacentini M: Targeting
homeostatic mechanisms of endoplasmic reticulum stress to increase
susceptibility of cancer cells to fenretinide-induced apoptosis:
The role of stress proteins ERdj5 and ERp57. Br J Cancer.
96:1062–1071. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ramírez-Rangel I, Bracho-Valdés I,
Vazquez-Macías A, Carretero-Ortega J, Reyes-Cruz G and
Vázquez-Prado J: Regulation of mTORC1 complex assembly and
signaling by GRp58/ERp57. Mol Cell Biol. 31:1657–1671. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Matter MS, Decaens T, Andersen JB and
Thorgeirsson SS: Targeting the mTOR pathway in hepatocellular
carcinoma: Current state and future trends. J Hepatol. 60:855–865.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chang Z, Shi G, Jin J, Guo H, Guo X, Luo
F, Song Y and Jia X: Dual PI3K/mTOR inhibitor NVP-BEZ235-induced
apoptosis of hepatocellular carcinoma cell lines is enhanced by
inhibitors of autophagy. Int J Mol Med. 31:1449–1456.
2013.PubMed/NCBI
|
